Kisspeptin-10: hormonal effects and the state of the research
Clinical review pending
What is known about kisspeptin-10, reproductive hormones and early human studies—and which questions remain open.
What is kisspeptin-10?
Kisspeptin-10 is a ten-amino-acid fragment of the natural hormone kisspeptin, which plays a major role in regulating reproduction. It is being studied in reproductive and sexual function and sold as a “research peptide.” Much of the human research concerns the closely related, longer natural form, kisspeptin-54. It is not an approved medicine.
How does it work?
Kisspeptin binds to receptors on GnRH neurons in the brain and stimulates GnRH release. This hormone in turn stimulates the pituitary hormones LH and FSH, which regulate the gonads. This role within the reproductive hormonal axis is well established in humans and animals. Other effects on brain regions that process sexual and emotional stimuli remain under investigation. The mechanism alone does not establish an approved treatment. Source Source
Is kisspeptin FDA-approved?
No. There is no FDA-approved kisspeptin product for any indication; it remains investigational. It was not among the peptides receiving a favorable assessment in the FDA’s 2026 compounding deliberations.
The 2026 WADA Prohibited List 1 prohibits kisspeptin and its agonist analogues in male athletes.
What does the research show?
Peer-reviewed human studies exist, but their conclusions are limited. Controlled studies by academic research groups, indexed in PubMed, describe kisspeptin’s effects on the brain’s processing of sexual and emotional stimuli in healthy men 2 3 and in women with low sexual desire 4. There is also well-studied stimulation of reproductive hormones, summarized in a review 5. The following limitations matter when interpreting these studies:
-
They are small studies at early stages of research.
-
They often examined brain-imaging findings rather than clinical endpoints.
-
Much of the research on sexual behavior used the longer form, kisspeptin-54.
These findings come from experimental research. They do not establish an approved, effective treatment.
The study described in the source article as the only one of kisspeptin-10 itself was small. In 2013, George and colleagues reported that a single intravenous dose increased LH levels in five men with type 2 diabetes and low testosterone and in seven healthy men 6. In four of the men with diabetes, LH and testosterone increased during an 11-hour infusion.
The study had no placebo group. It therefore offers evidence of feasibility, rather than proof of clinical benefit.
The study in women involved 32 premenopausal women with hypoactive sexual desire disorder. They received kisspeptin-54 in a crossover design. Brain imaging showed reduced activity in the left inferior frontal gyrus 4. This is an imaging finding, not a clinical treatment success.
Studies at a glance
| Hormone | Before infusion | After infusion | p-value |
|---|---|---|---|
| LH | 3.9 IU/L | 20.7 IU/L | 0.03 |
| Testosterone | 8.5 nmol/L | 11.4 nmol/L | 0.002 |
References provided in the source article
Sources: randomized human studies of kisspeptin and sexual/emotional brain processing (Comninos et al., Journal of Clinical Investigation, 2017, DOI: 10.1172/JCI89519 2 ; JCI Insight, 2018, DOI: 10.1172/jci.insight.121958 3 ; Thurston et al., JAMA Network Open, 2022, DOI: 10.1001/jamanetworkopen.2022.36131 4 ) and a review (Patel et al., Endocrine Reviews, 2024, DOI: 10.1210/endrev/bnad023 5 ), all indexed on PubMed.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.